|Kodiak CEO Victor Perlroth|
Ophthalmology biotech Kodiak Sciences raised $34 million in Series B financing to speed up its pipeline of ocular therapies.
The company, founded in 2009, recruited an undisclosed U.S.-based investor to lead the round, earmarking funds for its work on an unnamed disease of the eye. With the fundraise, Kodiak has pulled in more than $60 million for its work, the company said.
Kodiak is keeping its targets under wraps as it works through preclinical studies, putting its new funds toward early-stage research as it develops new therapies for retinal disease.
"This financing is further recognition of the potential of our pipeline and platform in retina," CEO Victor Perlroth said in a statement. "We now move another step closer to our goal of building a long-term and independent retina franchise company for the benefit of patients."
- read the statement